Therapeutic Equivalence Codes: How FDA Rates Generic Substitutability

Have you ever looked at your prescription bottle and wondered why the name on it doesn't match what your doctor wrote down? You aren't alone. In the United States, roughly 90% of prescriptions filled are for generic drugs. These medications save the healthcare system billions of dollars every year-about $370 billion annually, according to recent data from the Association for Accessible Medicines. But how do we know these cheaper alternatives work exactly like the expensive brand-name versions?

The answer lies in a system of letters and numbers known as therapeutic equivalence codes. This is the U.S. Food and Drug Administration's (FDA) official way of telling doctors, pharmacists, and patients whether a generic drug can safely replace a brand-name one. It’s not just a guess; it’s a rigorous scientific evaluation. Understanding these codes helps you navigate your medication with confidence, knowing that the pill in your hand has been vetted for safety and effectiveness.

What Are Therapeutic Equivalence Codes?

Therapeutic equivalence codes are alphanumeric labels assigned by the FDA to indicate whether a generic drug product is therapeutically equivalent to a reference listed drug (the brand-name version).

To get an 'A' rating-the gold standard for substitution-a generic drug must meet three strict criteria:

• Pharmaceutical Equivalence: The generic must contain the same active ingredient, in the same strength, dosage form (like a tablet or capsule), and route of administration (oral, topical, etc.) as the brand-name drug.
• Bioequivalence: The generic must be absorbed into the bloodstream at the same rate and extent as the brand-name drug. This means it works in your body in the same way.
• Clinical Effect and Safety: The product must produce the same clinical effect and safety profile as the prescribed product under the conditions specified in the labeling.

This system is published in the Orange Book, officially titled "Approved Drug Products with Therapeutic Equivalence Evaluations." First published in 1980 following the Hatch-Waxman Amendments of 1984, the Orange Book is the primary resource for checking if a generic can be substituted. If a drug has an 'A' code, you can expect it to perform identically to the brand-name version.

Decoding the Letters: A vs. B Ratings

The TE code system uses a multi-letter classification. The first letter is the most critical part of the code. Here is what you need to know about the two main categories: 'A' and 'B'.

The 'A' Rating: Safe for Substitution

If a drug starts with the letter 'A', it is considered therapeutically equivalent. This is the green light for pharmacists to substitute the generic for the brand-name drug without needing extra permission from your doctor. About 90% of generic drugs in the U.S. market carry an 'A' rating.

You might see suffixes like AB1, AB2, AB3, or AB4. These don’t mean the drug is different; they simply indicate that there are multiple reference listed drugs (brand names) for that specific strength and dosage form. For example, if two different companies make the brand-name version of a drug, generics will be compared against both, resulting in different sub-codes. The bottom line remains the same: an 'A' rated drug is safe and effective.

The 'B' Rating: Needs More Investigation

A 'B' rating does not necessarily mean the drug is unsafe or ineffective. Instead, it means the FDA requires further investigation to determine therapeutic equivalence. This often happens with complex drug products where standard testing methods aren't enough to prove bioequivalence easily.

Common 'B' codes include:

• BC: Extended-release dosage forms.
• BD: Active ingredients with documented bioequivalence problems.
• BE: Delayed-release oral dosage forms.
• BN: Aerosol-nebulizer drug delivery systems.
• BP: Potential bioequivalence problems.
• BT: Topical products with bioequivalence issues.
• BX: Insufficient data to determine therapeutic equivalence.

Dr. Duxin Sun, a Professor of Pharmaceutics at the University of Michigan, noted in a 2022 article that current TE codes for topical, inhaled, and complex injectable products may not adequately reflect therapeutic equivalence due to the insufficiency of standard bioequivalence measures. This is why many complex generics still sit in the 'B' category despite potentially being clinically equivalent.

How Pharmacists Use TE Codes Daily

When you drop off a prescription, your pharmacist doesn't just grab any generic off the shelf. They verify the TE status. According to a 2023 American Pharmacists Association study, pharmacists spend an average of 2.7 minutes per prescription verifying this status. This quick check contributes to an estimated $1.2 billion in annual healthcare savings through appropriate generic substitution.

In 49 U.S. states, laws permit automatic substitution of 'A'-rated generics without physician intervention. However, challenges arise with 'B'-rated products. A 2022 American Medical Association survey revealed that 42% of physicians expressed confusion about how to interpret 'B' codes. Sometimes, pharmacists may incorrectly refuse to substitute a 'B'-rated product that is actually appropriate, leading to unnecessary costs for patients who then have to pay for the brand-name version.

If you receive a 'B'-rated generic, don't panic. It just means the substitution process involves a bit more scrutiny. Your pharmacist might call your doctor to confirm, or they might ask you to pick up the brand-name drug if the 'B' code indicates significant uncertainty. Always feel free to ask your pharmacist why a specific generic was chosen or rejected.

Why Some Drugs Don't Get TE Codes

Not every drug gets a therapeutic equivalence code. The FDA explicitly excludes over-the-counter (OTC) drugs from TE code assignments. This is because OTC drugs are evaluated differently, focusing on consumer self-care rather than physician-prescribed substitution.

Additionally, stand-alone New Drug Applications (NDAs), which are typically for new brand-name drugs developed entirely by one company, are designated as Reference Listed Drugs (RLDs) but do not receive TE codes themselves. TE codes are primarily for multisource prescription products-that is, generics competing with the RLD.

505(b)(2) NDAs, which are applications for drugs that rely partly on existing data (like a new combination of two old drugs), may receive either 'A' or 'B' ratings depending on the evidence submitted. This flexibility allows the FDA to evaluate novel modifications while maintaining safety standards.

The Future of Therapeutic Equivalence

The landscape of generic drugs is changing. As pharmaceutical science advances, we are seeing more complex drug products-such as inhalers, patches, and extended-release formulations-that are harder to test for bioequivalence. Between 2018 and 2022, the FDA reported a 22% increase in 'B'-rated applications for complex generics.

In response, the FDA released a draft guidance document in 2022 titled "Evaluation of Therapeutic Equivalence." This guidance proposes updates to address challenges with complex drug products. The agency aims to modernize TE evaluations, with a target of reducing 'B'-rated products for complex generics by 30% by 2027. This effort involves expanding Product-Specific Guidances (PSGs) to provide detailed bioequivalence recommendations for specific drug products.

Industry analysts predict that the TE code system will evolve to incorporate more real-world evidence alongside traditional bioequivalence studies. This shift could help resolve ambiguities around 'B' codes, ensuring that patients have access to safe, effective, and affordable generics even for complex medications.

Practical Tips for Patients

Understanding therapeutic equivalence codes empowers you to manage your health better. Here are a few practical steps you can take:

1. Check the Orange Book: If you're curious about a specific drug, you can look it up on the FDA's Orange Book website. It’s searchable and provides clear explanations of each code.
2. Ask Questions: If your pharmacist substitutes a generic and you notice a difference in how you feel, talk to them. While rare, individual responses can vary slightly due to inactive ingredients (fillers, dyes).
3. Don't Assume 'B' Means Bad: Remember that a 'B' code often reflects regulatory caution rather than clinical failure. Many 'B'-rated drugs are perfectly safe and effective.
4. Review State Laws: Know your state’s substitution laws. Most allow automatic substitution of 'A'-rated generics, but rules for 'B'-rated drugs vary.

By staying informed, you can ensure that you’re getting the best possible care without paying more than necessary. The TE code system is a vital tool in making healthcare accessible, and understanding it helps you participate actively in your own treatment plan.